STOCK TITAN
  1. Home
  2. Sec-filings
  3. GANX
  4. [Form 4] Gain Therapeutics, Inc. Insider Trading Activity

Gain Therapeutics (GANX) awards 25,000 options to director at $1.68 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Gain Therapeutics, Inc. reported that director Hans Peter Hasler received a grant of 25,000 stock options on 2026-07-15. The options have an exercise price of $1.68 per share for Gain Therapeutics common stock and expire on 2036-07-15. They vest in 12 equal monthly installments commencing on July 24, 2026, conditioned on his continuous service through each vesting date. Following this award, he directly holds 25,000 derivative securities linked to common stock. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.
Insider HASLER HANS PETER
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) F1 25,000 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct)
Footnotes (1)
  1. F1. The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.
Options granted 25,000 shares Stock options granted to director Hans Peter Hasler on 2026-07-15
Exercise price $1.68 per share Conversion or exercise price of the stock option award
Underlying shares 25,000 shares Common stock underlying the reported stock options
Expiration date 2036-07-15 Final expiration date of the stock option grant
Vesting schedule 12 monthly installments Vesting commences on July 24, 2026, subject to continuous service
Holdings after grant 25,000 derivative securities Total stock options held directly after the reported transaction
Stock Option (right to buy) financial
"Security title is reported as "Stock Option (right to buy)""
conversion or exercise price financial
"Field "conversion_or_exercise_price" is listed as 1.6800"
continuous service financial
"Vesting is subject to the Reporting Person's continuous service"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did Gain Therapeutics (GANX) disclose for Hans Peter Hasler?
Gain Therapeutics (GANX) disclosed that director Hans Peter Hasler received a grant of 25,000 stock options. These options give him the right to buy Gain Therapeutics common stock at $1.68 per share, expiring on 2036-07-15, as part of his director compensation.

What is the exercise price and expiration date of the new GANX stock options?
The new options for Gain Therapeutics (GANX) have an exercise price of $1.68 per share and expire on 2036-07-15. This means Hasler can buy GANX common shares at $1.68 anytime before that expiration date, subject to vesting conditions.

How do the Gain Therapeutics (GANX) options granted to Hans Peter Hasler vest?
The options granted to Hasler by Gain Therapeutics (GANX) vest in 12 equal monthly installments starting July 24, 2026. Each monthly tranche vests only if he remains in continuous service through the respective vesting date, aligning vesting with ongoing board service.

How many Gain Therapeutics (GANX) derivative securities does Hans Peter Hasler hold after this grant?
After this grant, Hans Peter Hasler directly holds 25,000 derivative securities tied to Gain Therapeutics (GANX) common stock. These represent the full option award reported, as indicated by the post-transaction holdings in the Form 4 data.

Was the GANX option grant to Hans Peter Hasler made under a Rule 10b5-1 plan?
No, the Gain Therapeutics (GANX) option grant to Hasler was not made under a Rule 10b5-1 trading plan. The filing’s Rule 10b5-1 checkbox is explicitly unchecked, indicating no such pre-arranged plan applies to this award.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HASLER HANS PETER
(Last)(First)(Middle)
C/O GAIN THERAPEUTICS, INC.
4800 MONTGOMERY LANE, SUITE 220
(Street)
BETHESDA MARYLAND 20814
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Gain Therapeutics, Inc. [ GANX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.6807/15/2026A25,000 (1)07/15/2036Common Stock25,000$0.0025,000D
Explanation of Responses:
1. The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.
/s/ Hans Peter Hasler07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR